ASH 2022 | An update on targeted therapy in pediatric leukemia
In this video, Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, comments on the importance of precision medicine and targeted therapy trials in pediatric leukemia, and highlights the important role that next-generation sequencing (NGS) has played in this disease. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Aleta Biotherapeutics: Consultancy; Beam Therapeutics: Research Funding; bluebird bio: Consultancy; Syndax Pharmaceuticals: Consultancy; Kura Oncology: Consultancy, Research Funding; GSK: Consultancy; Incyte Corporation: Research Funding.
